Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Results on Sedar

<< Previous

Bullboard Posts

Next >>

Comment by word99on Mar 04, 2021 10:22am

164 Views

Post# 32714271

RE:RE:RE:Results on Sedar

lscfa wrote:
$105,000 revenue in Q4 = $80,000 USD = 10 kilos of 1067 to R+F.

On September 13, 2019, the Company entered into a manufacturing and supply agreement, pursuant to which the Company shall manufacture, test, label, package, store and supply R&F a minimum of 10 kilograms per year of skin lightening compound TFC-1067 for use in the United States, Canada, Australia and Japan for US$8,000 per kilogram beginning in 2020. In consideration for these services, R&F shall also make the following license fee and milestone payments to the Company:

The unknown is the maximum amount R + F needs going forward.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property